- GuruFocus.com•6 days ago
CEO & President of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) Mark Pruzanski sold 35,000 shares of ICPT on 09/20/2016 at an average price of $165 a share.
- Investor's Business Daily•6 days ago
Gilead is trailing Intercept in the battle against NASH, Credit Suisse analyst Alethia Young said Thursday.
- Barrons.com•6 days ago
Much attention is being paid to Gilead Sciences (GILD) and its non-alcoholic steatohepatitis, or NASH, program following Allergan's (AGN) purchases of small biotech companies operating in the space. Gabelli's ...
Intercept Pharmaceuticals, Inc. (ICPT)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||168.00 x 200|
|Ask||171.00 x 100|
|Day's Range||166.51 - 172.75|
|52wk Range||89.76 - 217.99|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-11.94|
|Avg Vol (3m)||447,198|
|Dividend & Yield||N/A (N/A)|